Spectrum of Neurocognitive Involvement in Children with Liver Disease

Create Account

Availability

Registration Required

Online Meeting

Sep 22, 2026 9:00 AM - 10:00 AM ET

Cost

$0.00

Credit Offered

No Credit Offered

Description
Learning Objectives
Faculty and Disclosures

Neurocognitive involvement in children with chronic liver disease (CLD) or portosystemic shunting (PSS) is an under recognized but clinically meaningful complication with implications for neurodevelopment and long-term outcomes. Although hepatic encephalopathy is well defined in adults, children with liver disease exhibit distinct and often subtle neurocognitive manifestations that are not adequately captured by adult-based definitions. There is an awareness gap in routine pediatric hepatology care. This webinar is intended for hepatologists, gastroenterologists, transplant coordinators, surgeons, physician assistants, nurses, fellows and trainees. Others with an interest in neurocognitive involvement in children with liver disease are also welcome to attend.

Upon completion of this activity, a participant should be able to:

• Comprehend the clinical spectrum of neurocognitive involvement of chronic liver disease
• Identify appropriate questions to ask to determine the level of neurocognitive symptoms in children
• Develop recommendations for early interventions before level of transplantation
• Comprehend cellular and molecular basis of neurocognitive involvement in transplant decisions

This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence in Accredited Continuing Education by members of the Continuing Medical Education Committee. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Valerie McLin, MD

Cristina Padros Fornieles, MD

Sharon DeMorrow, PhD